Neoadjuvant hormone therapy followed by radical prostatectomy in men with stage T3 prostate cancer yields 5-year progression free survival rates comparable to those achieved with neoadjuvant radiation therapy, according to the results of a phase II feasibility study.
Dr. Isaac J. Powell from Wayne State University Medical Center, Detroit, and colleagues treated 61 men for 4 months with neoadjuvant hormonal therapy consisting of goserelin and flutamide. Most patients (97%) had stage T3 prostate cancer and the remaining patients had stage T4 cancer. Overall, 39% were classified as having bulky disease with tumor size greater than 4 cm.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!